Page 26 - Recursion Pharmaceuticals News Today

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) insider Shafique Virani sold 18,000 shares of the stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $9.25, for a total transaction of $166,500.00. Following the completion of the sale, the insider now directly owns 140,351 shares […]

As investors begin to see light at the end of the tunnel, their risk appetite, which had vanished amid recession risks and volatility, is coming back, creating chances of major investments in high-risk...

Stakeholders need to convene honest, actionable discussions about the challenges and the safeguards needed to address appropriate use of artificial intelligence in health care.

An innovation boom, coupled with a dose of western hospitality, has lured many venture capitalists to Rocky Mountain states like Colorado and Utah.

AI has driven markets over the past months but have market expectations become too detached from reality? Jesmond Mizzi Financial Advisors’ chief investment off

You can find some great AI investment opportunities by looking at the stocks in Wood's Ark Invest portfolio.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) Director Blake Borgeson sold 17,770 shares of the company’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $11.16, for a total transaction of $198,313.20. Following the completion of the sale, the director now directly owns 7,469,615 shares of […]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) Director Blake Borgeson sold 17,770 shares of the firm’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $11.16, for a total value of $198,313.20. Following the sale, the director now directly owns 7,469,615 shares in the company, valued […]

Needham & Company LLC reiterated their buy rating on shares of Recursion Pharmaceuticals (NASDAQ:RXRX – Free Report) in a research note released on Wednesday, Benzinga reports. They currently have a $17.00 price target on the stock. Other equities analysts have also recently issued reports about the company. Morgan Stanley began coverage on Recursion Pharmaceuticals in […]

Until it can get some recurring revenue going, it'll be a risky stock to buy.